0.00Open7.50Pre Close0 Volume1 Open Interest68.00Strike Price0.00Turnover61.26%IV1.06%PremiumNov 29, 2024Expiry Date6.71Intrinsic Value100Multiplier4DDays to Expiry0.79Extrinsic Value100Contract SizeAmericanOptions Type0.9433Delta0.0232Gamma11.15Leverage Ratio-0.0686Theta0.0072Rho10.52Eff Leverage0.0091Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet